Mednet Logo

In which patients with early stage rectal cancer treated according to the PROSPECT paradigm do you recommend adjuvant chemotherapy?

Current NCCN guidelines do not include adjuvant chemotherapy for patients treated in this fashion; however, in the PROSPECT trial itself, an additional 6 cycles of adjuvant FOLFOX was "suggested but not mandated", and 75% of patients did receive adjuvant chemotherapy.
3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on

Great question and great observation. The most recent NCCN guidelines (version 1.2024-page REC-6) clearly listed neoadjuvant chemotherapy without radiation as an option for patients with no T4 disease eligible for sphincter-sparing surgery. After the neoadjuvant chemotherapy, if tumor regression is ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · UH Seidman Cancer Center, Case Western Reserve University
Answered on

If I choose to pursue the PROSPECT regimen, I would pursue it in its entirety and would advocate for adjuvant chemo for all patients unless AC poses additional risks for any reason. The PROSPECT manuscript does not say why 25% of patients did not receive AC after the surgery. My guess is a significa...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on · Updated on

When the PROSPECT trial data was published in the print form in the New England Journal of Medicine back in July 2023 (Schrag et al., PMID 37272534), we submitted our commentary to the New England Journal of Medicine addressing this very question in early August 2023. (Copur et al. N Eng J Med, unpu...

Join for free or sign in to see the full answer